top of page
CaliciX™ – EIDD-1931 Antiviral Therapy for Feline Calicivirus–Associated Sto
CaliciX™ is a feline-specific antiviral treatment developed to support cats affected by feline calicivirus (FCV) — a common viral infection responsible for painful oral disease in cats.
 
Often referred to as calicivirus, feline calici, or virus calici, this infection is a leading cause of stomatitis, gingivitis, mouth ulcers, and chronic oral understanding in cats. StomatiCure™ is designed to target the virus directly, rather than only managing symptoms.
 
What Is Feline Calicivirus in Cats?
Feline calicivirus in cats is a highly contagious viral disease. Cats with FCV may develop persistent inflammation in the mouth, making eating and grooming painful.
 
Common search terms such as fcv cat, fcv in cats, and calici in cats all refer to this same condition.
 
Common Calicivirus Cat Symptoms
Cats suffering from calicivirus may show:
  • Severe gum inflammation
  • Painful mouth ulcers on the tongue, gums, or cheeks
  • Excessive drooling
  • Bad breath
  • Difficulty eating or swallowing
  • Reduced appetite and weight loss
 
These calicivirus symptoms can worsen over time, especially in chronic or recurrent cases.
 
How CaliciX™ Helps Cats With Calicivirus
Each CaliciX™ capsule contains 15 mg of EIDD-1931, the active antiviral form of molnupiravir, formulated specifically for cats.
 
Unlike supportive care alone, CaliciX™ works by:
  • Targeting feline calicivirus replication
  • Reducing viral activity at the source
  • Supporting healing of oral tissues
 
This makes CaliciX™ a targeted option for calicivirus cats treatment, particularly when oral disease is persistent or recurrent.
 
Conditions Supported by CaliciX™
CaliciX™ may be used under veterinary guidance to support cats diagnosed with:
  • Feline Chronic Gingivostomatitis (FCGS)
  • Juvenile gingivitis
  • Caudal stomatitis
  • Viral mouth ulcers
  • Glossitis associated with calicivirus
 
Many cat parents report improvements in comfort, appetite, and overall quality of life when StomatiCure™ is included in a veterinarian-guided treatment plan.
 
Why Choose CaliciX™ for FCV in Cats?
✔ Designed specifically for feline calicivirus
✔ Contains EIDD-1931, not human molnupiravir
✔ Targets the viral cause, not just symptoms
✔ Supports long-term management of calici symptoms
 
If your cat suffers from calicivirus cat symptoms or recurring oral pain related to feline calicivirus, CaliciX™ offers a modern antiviral approach built specifically for feline needs.

Dosage Adjustment Guidance
Dosage may be adjusted by a licensed veterinarian based on the cat’s clinical response.

Signs that may indicate insufficient dosage include:
  • Persistent drooling
  • Pain or discomfort while chewing
  • Slow healing of oral ulcers
  • Unintended weight loss
 
Any dosage increase should remain within the recommended range and must be performed only under veterinary direction.
 
Veterinary Use Notice
Use under veterinary supervision. Dosage and treatment duration may vary based on the severity of FCV in cats and clinical response.

CaliciX™ – EIDD-1931 Antiviral Therapy for Feline Calicivirus–Associated Sto

SKU: MF15
$49.00Price
Quantity

  • CaliciX™ – EIDD-1931 Oral Capsules (15 mg)

    Antiviral agent for feline calicivirus–associated stomatitis and oral inflammatory disease

    For veterinary use only

    Active Ingredient

    • EIDD-1931 (β-D-N4-hydroxycytidine) – 15 mg per capsule
    • Pharmacologically equivalent to ~66 mg molnupiravir (EIDD-2801)

    Indications
    CaliciX™ is intended for the management of severe oral inflammatory diseases driven by chronic or high-load FCV infection, including:

    Primary Indications

    • Feline Chronic Gingivostomatitis (FCGS)– particularly cases with confirmed or suspected calicivirus involvement
    • Juvenile Onset Gingivitis/Stomatitis
    • Caudal Stomatitis
    • Ulcerative Stomatitis
    • Viral Glossitis & Lingual Ulceration
    • Buccal, Labial & Palatal Ulcers of Viral Origin

    Clinical Signs

    • Oral pain, reluctance to eat
    • Ptyalism (drooling)
    • Halitosis
    • Dysphagia
    • Mucosal ulceration
    • Gingival bleeding
    • Weight loss / poor body condition due to oral discomfort

    CaliciX™ may be used as primary antiviral therapy or as part of a multimodal treatment plan (e.g., analgesia, dental care, antibiotics for secondary infection).

    Mechanism of Action
    EIDD-1931 is the active intracellular metabolite of molnupiravir.

    Once absorbed, it is phosphorylated to its triphosphate form and incorporated into viral RNA by RNA-dependent RNA polymerase (RdRp), causing:

    • Lethal mutagenesis
    • Rapid decline in viral replication
    • Reduced viral load within mucosal tissues

    Compared with EIDD-2801, CaliciX's EIDD-1931 demonstrates:

    • Higher intrinsic antiviral potency
    • More predictable pharmacokinetics
    • No requirement for enzymatic conversion from prodrug form

    Reference potency data shows EIDD-1931 is 4.4x - 10× more potent than molnupiravir.  

    Reference: ht​​​tps://pmc.ncbi.nlm.nih.gov/articles/PMC9227765/

    Suggested Dosing (Vet-Determined)

    Standard dosing varies with severity, weight, and multimodal protocols. Common clinical practice ranges:

    • Mild–Moderate Viral Stomatitis 1–2 mg/kg PO q12h
    • Severe FCGS, Caudal Stomatitis, Extensive Ulceration 2–3 mg/kg PO q12h
    • Juvenile Gingivitis 1 mg/kg PO q12h, adjust based on response

    Duration:
    4–12 weeks depending on lesion severity, clinical response, and relapse risk.

    Combination therapy:

    Often paired with:

    • Analgesics (e.g., buprenorphine or meloxicam)
    • Doxycycline for secondary bacterial overgrowth
    • Chlorhexidine oral careNutritional support / appetite stimulants

    Pharmacokinetics

    • High oral bioavailability in felines
    • Rapid intracellular activation
    • Excellent distribution into oral mucosa, gingival tissues, and saliva
    • Stable therapeutic levels with BID dosing
    • Lower mg/kg requirement due to high potency
    • Safety Profile

    Contraindications:

    1. Pregnant or breeding cats (theoretical mutagenicity risk)
    2. Severe hepatic impairment
    3. Caution in renal insufficiency if combined with NSAIDs

    Monitoring:
    For extended therapy (>6 weeks):

    • CBC every 2–4 weeks
    • ALT/AST if concurrent medications used
    • Body weight and pain scoring

    Adverse effects are typically mild and dose-dependent (GI upset, transient lethargy).

    Clinical Expectations
    Veterinarians may expect improvement in:

    1. Drooling and oral pain within 3–7 days
    2. Ulcer depth reduction within 1–2 weeks
    3. Appetite return and weight gain within 2–3 weeks
    4. Mucosal healing and inflammation reduction over 4–12 weeks

    Best outcomes are seen when FCV involvement is confirmed or strongly suspected.

bottom of page